2023-508750-25-00进行中（未招募）3 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adenoassociated Virus Serotype 8-mediated Gene Transfer of Glucose-6-phosphatase in Patients With Glycogen Storage Disease Type Ia.
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
- 试验地点
- 7
- 主要终点
- "Percent change from Baseline to Week 48 in daily cornstarch intake for the DTX401 Group compared with the Placebo Group."
研究概览
简要总结
To evaluate the efficacy of DTX401 to reduce or eliminate dependence on exogenous glucose replacement therapy needed to maintain glucose control.
研究设计
- 分配方式
- Randomized
- 主要目的
- The Follow-up Period
- 盲法
- Double (Subject, Investigator, Monitor)
入排标准
- 年龄范围
- 0 years 至 65+ years（65+ Years, 0-17 Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Male and female patients ≥ 8 years of age at time of informed consent or assent.
- •Subject has a diagnosis of GSDIa confirmed by deficient enzymatic activity (on liver biopsy), or by molecular testing of G6PC gene revealing 2 pathogenic mutations. In the case where only a single pathogenic mutation is identified, clinical diagnosis is compatible with GSDIa and absence of characteristic features of GSDIb (ie, chronic neutropenia, inflammatory bowel disease).
- •Subject is currently receiving a therapeutic regimen of cornstarch (or equivalent), following international guidance/recommendations (Appendix 1) with stable nutrition, glycemic, and clinical status as evidenced by: a. no more than a 10% variation in weekly average daily cornstarch (or equivalent) intake over the last 4 weeks. b. no more than a 25% variation in weekly average daily non-cornstarch carbohydrate over the last 4 weeks. c. No more than 15% variation in weekly percentage of values in the target blood glucose range (60-120 mg/dL) over the last 4 weeks as measured by CGM and corroborated by SMBG. If adequate corroboration is not observed, this assessment should be made by SMBG. d. No hospitalization for hypoglycemia and no severe hypoglycemic event (SHE) during the 4-week period preceding randomization and dosing (see Section 10.4.2 for more detail on SHE), notwithstanding events of hypoglycemia due to unavoidable and unforeseeable events (eg, infection, trauma) that transiently prevent the subject from tolerating enteral intake or acutely change the subject's metabolic demands, provided that the subject quickly returns to their prior physiologic state.
- •Subject is willing
- •Subject is willing and able to comply with study procedures, requirements, and study medication, including periodic inpatient hospitalization or admission in a research facility; CFC studies; frequent blood collection; wearing a CGM device for the duration of the study (and excluding the use of any non-study CGM or flash glucose device); performing capillary glucose measurements according to the protocol using a study approved glucometer (and excluding the use of any other glucometer); completing an eDiary to track daily cornstarch, diet intake, and reasons for doing SMBG routinely throughout the study as required by the protocol; and completing patient-reported questionnaires. Subject must strictly comply with prednisolone/placebo prednisolone prescription including changes in prescription that may be implemented during the study by the Investigator, if needed. (See Section 9.2, Prednisolone Taper.) If < 18 years (or as required by region), has a parent or legal guardian willing and able to assist with study requirements.
- •From the period following informed consent through the duration of participation in the study, female subjects of childbearing potential and fertile male subjects must consent to use highly effective contraception as defined by the Food and Drug Administration (FDA) and Clinical Trial Facilitation Group Recommendations Related to Contraception and Pregnancy Testing in Clinical Trials (Version 1.1 dated 21 Sep 2020). Female subjects must agree not to become pregnant and male subjects must agree not father a child or donate sperm for at least 48 weeks after the last dose of IP if they decide to withdraw early from the study.
- •Subject is willing and able to provide written informed consent after the study has been explained and before any study-related procedures are performed. If < 18 years (or as required by region), willing and able to provide written assent and have a parent or legal guardian willing and able to provide written informed consent after the study has been explained and before any study-related procedures are performed."
排除标准
- •Detectable pre-existing antibodies to the AAV8 capsid during Sceening.
- •History of liver transplant, including hepatocyte cell therapy/transplant.
- •History of severe hepatic fibrosis or cirrhosis as evidenced by any of the following: portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy, or a liver biopsy with evidence of stage III fibrosis.
- •Presence of liver adenoma > 5 cm in size or presence of liver adenoma > 3 cm and ≤ 5 cm in size with a documented annual growth rate of ≥ 0.5 cm per year.
- •Significant hepatic injury or dysfunction as evidenced by imaging or any of the following laboratory abnormalities from 2 consecutive samples (collected at least 4 weeks apart). Liver function tests may be repeated during Screening at the Investigator's discretion; those with initially abnormal values may be retested and the subject will qualify for this criterion if the most recent results during Screening are within the allowed range: − ALT or aspartate aminotransferase > 2.5 × the ULN − Total bilirubin > ULN (unless the subject has Gilbert syndrome) − Alkaline phosphatase > ULN, with gamma-glutamyl transferase > ULN
- •Presence or history of hepatitis B virus infection, hepatitis C virus infection, or both.
- •Non-fasting triglycerides ≥ 1000 mg/dL. For the purposes of this study, non-fasting refers to the longest fasting period that each individual subject is able to tolerate. Depending on the meal and cornstarch schedule, the blood draw could occur in the morning before breakfast or before the first dose of cornstarch.
- •Human immunodeficiency virus infection AND any of the following: CD4+ cell count < 350 cells/mm3, change in antiretroviral therapy regimen within 6 months before baseline, or plasma viral load > 200 copies/ml on 2 separate occasions as measured by polymerase chain reaction.
- •Presence or history of any disease or condition that, in the Investigator's opinion, would interfere with the subject's safety or ability to participate in the study or would significantly affect interpretation of study results. This includes any intercurrent febrile or nonfebrile illness including common viral infections, epidemic influenza, and other viral illnesses, and Coronavirus disease 2019 (COVID-19) until full clinical recovery.
- •Female subjects of childbearing potential who have a positive pregnancy test who are unwilling to use contraception, or are unwilling to have additional pregnancy tests during the study.
- •Pregnant, breastfeeding, or planning to become pregnant (self or partner) at any time during the study.
- •Presence or history of any hypersensitivity to the excipients of DTX401 or placebo or to prednisolone, or inability to swallow capsules that, in the judgment of the Investigator, places the subject at increased risk for adverse effects.
- •Current or previous participation in another gene transfer study.
- •Use of any IP or investigational medical device within 3 months preceding screening or planning to use at any time during the study.
- •History of illicit drug use within 60 days prior to Screening or positive results from a 9-panel urine drug screen prior to dosing and completed at 2 time points at least 4 weeks apart. Positive results that are due to a prescribed medication may be allowed if not impacting glycemic control and liver function and after agreement with the Sponsor. For the purposes of this protocol, the use of recreational cannabis products is not allowed, even if legal in the region where the patient lives."
结局指标
主要结局
"Percent change from Baseline to Week 48 in daily cornstarch intake for the DTX401 Group compared with the Placebo Group."
"Percent change from Baseline to Week 48 in daily cornstarch intake for the DTX401 Group compared with the Placebo Group."
次要结局
- "1. Change from Baseline to Week 48 in number of total daily doses of cornstarch 2. Change from Baseline to Week 48 in the percentage of glucose values in hypoglycemic range (<70 mg/dL [3.9 mmol/L]), assessed for noninferiority; if non-inferiority is established, the endpoint will be tested for superiority. 3. PGIC assessment score at Week 48. "
- "4. Change from Baseline to Week 48 in time to hypoglycemia (<54 mg/dL [3.0 mmol/L]) during the CFC. 5. Change from Baseline to Week 48 in percentage of glucose values in the range of 70-120 mg/dL [3.9-6.7 mmol/L], assessed for noninferiority; if non-inferiority is established, the endpoint will be tested for superiority."
- 6. Incidence, severity, and relationship to investigational product of TEAEs, TEAEs of special interest, serious TEAEs, related TEAEs, discontinuations from study or investigational product due to AEs, and fatal AEs.
研究者
Medical Information
Scientific
Ultragenyx Pharmaceutical Inc.
研究点 (7)
Loading locations...
相似试验
招募中
2 期
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Chronic Inducible Urticaria2024-516988-87-00Celldex Therapeutics Inc.114
招募中
2 期
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)NCT07287670Mediar Therapeutics85
招募中
2 期
Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)NCT07286747University Hospital Schleswig-Holstein390
招募中
2 期
A study to evaluate the safety and effectiveness of a new gene therapy (XC001) for people with coronary artery disease and reduced heart function who are undergoing bypass surgery but may not receive complete blood flow restoration (EXACT-CABG)2025-521325-33-00Xylocor Therapeutics Inc.90
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainNCT07285018Eli Lilly and Company150